Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Rajesh Bakshi"'
Autor:
Frank A. Hoffmann, Anastasiya Trenova, Miguel A. Llaneza, Johannes Fischer, Giacomo Lus, Dorothea von Bredow, Núria Lara, Elaine Lam, Marlies Van Hoef, Rajesh Bakshi
Publikováno v:
BMC Neurology, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background Patients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often experience injection-site reactions and injection-site pain, which together with other side-effects (such as flu
Externí odkaz:
https://doaj.org/article/51918f7a767b4598b37f1092b4e301ba
Autor:
Frank Kloprogge, Lesley Workman, Steffen Borrmann, Mamadou Tékété, Gilbert Lefèvre, Kamal Hamed, Patrice Piola, Johan Ursing, Poul Erik Kofoed, Andreas Mårtensson, Billy Ngasala, Anders Björkman, Michael Ashton, Sofia Friberg Hietala, Francesca Aweeka, Sunil Parikh, Leah Mwai, Timothy M E Davis, Harin Karunajeewa, Sam Salman, Francesco Checchi, Carole Fogg, Paul N Newton, Mayfong Mayxay, Philippe Deloron, Jean François Faucher, François Nosten, Elizabeth A Ashley, Rose McGready, Michele van Vugt, Stephane Proux, Ric N Price, Juntra Karbwang, Farkad Ezzet, Rajesh Bakshi, Kasia Stepniewska, Nicholas J White, Philippe J Guerin, Karen I Barnes, Joel Tarning
Publikováno v:
PLoS Medicine, Vol 15, Iss 6, p e1002579 (2018)
BackgroundThe fixed dose combination of artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated Plasmodium falciparum malaria. Relatively lower cure rates and lumefantrine levels have been reported in young children and in pr
Externí odkaz:
https://doaj.org/article/c7efdb206c804baa952877e301ae94bd
Publikováno v:
American Heart Journal. 168(5):632-644
Fingolimod, a sphingosine-1-phosphate receptor (S1PR) modulator, was the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis; it reduces autoreactive lymphocytes' egress from lymphoid tissues by down-regulating S1P
Autor:
Núria Lara, Miguel A. Llaneza, Frank A. Hoffmann, Elaine Lam, Giacomo Lus, Dorothea von Bredow, Anastasiya G. Trenova, Rajesh Bakshi, Johannes Fischer, Marlies Van Hoef
Publikováno v:
BMC Neurology
RUNA. Repositorio da Consellería de Sanidade e Sergas
Servizo Galego de Saúde (SERGAS)
BMC Neurology, Vol 17, Iss 1, Pp 1-9 (2017)
RUNA. Repositorio da Consellería de Sanidade e Sergas
Servizo Galego de Saúde (SERGAS)
BMC Neurology, Vol 17, Iss 1, Pp 1-9 (2017)
Patients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often experience injection-site reactions and injection-site pain, which together with other side-effects (such as flu-like symptoms) resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c26e31d0830e9e639b1d2351d8f24f78
http://hdl.handle.net/11591/389327
http://hdl.handle.net/11591/389327
Autor:
Dieter A. Häring, Rajesh Bakshi
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 22(5)
Publikováno v:
International Journal of Dermatology. 45:154-157
Objectives An open-label study was performed to assess the efficacy and safety of terbinafine in the treatment of eumycetoma. Methods Single-center, open-label study, including 27 patients with signs and symptoms of eumycetoma which had developed wit
Publikováno v:
Clinical Therapeutics. 17:30-37
In a randomized, double-blind, parallel-group, multicenter study, the efficacy and tolerability of diclofenac dispersible were compared with placebo in the treatment of acute soft-tissue injuries. Patients seen within 48 hours of a soft-tissue injury
Publikováno v:
Current Medical Research and Opinion. 12:459-465
The efficacy and tolerability of a new dispersible formulation of diclofenac were evaluated in a randomized, double-blind, placebo-controlled, multi-centre study in patients aged 60 to 80 years suffering from osteoarthritis. A total of 314 elderly pa
Autor:
Boni E. Elewski, Carol Opper, Judit Nyirady, Bardur Sigurgeirsson, Bin Cai, Phoebe Rich, Rajesh Bakshi
Publikováno v:
The Journal of dermatological treatment. 17(1)
Terbinafine is an established drug for the treatment of toenail onychomycosis. Minimizing the total dose of terbinafine and giving it intermittently could improve tolerability as well as compliance, provided efficacy is not compromised.Two identical
Publikováno v:
Annals of Pharmacotherapy. 48:944-944